OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.
- Source
- Decrypt
- Published
- 2026-10-20 21:46 UTC
- Cache updated
- 2026-10-20 21:56 UTC
This page shows only the title, summary, and source metadata. Read the full story at the original source.
Open original ↗Check transfer fees